Internal Medicine III, Center for Integrated Oncology, University of Bonn, Bonn, Germany.
J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10. doi: 10.1007/s00432-010-0887-7. Epub 2010 Apr 21.
Recently, a subset of natural killer T lymphocytes termed "cytokine-induced killer (CIK) cells" has been described. To build an international registry, we collected the clinical data and treatment of patients with cancer using CIK cells from the literature and the respective investigators. This registry is expected to set a new set of standards on the reporting of results from clinical trials using CIK cells. A standardized reporting system will accelerate discoveries and allows us to improve treatment to benefit the patients.
We searched in PubMed for "CIK cells clinical trials".
Within the 867 matches found, 11 clinical trials with CIK cells were identified. Within these trials, 426 patients were treated, of which 313 were male, and 113 were female. Most trials included male patients with hepatocellular carcinoma, gastric cancer, and Hodgkin or non-Hodgkin disease. In 10 of 11 studies, autologous CIK cells were used. The total number of CIK cells injected ranged from 21.9 × 10(7) to 5.2 × 10(10). The number of CIK cells used per infusion ranged from 7.2 × 10(6) to 2.1 × 10(10). Patients were treated with up to 40 infusions of CIK cells. Of the 384 patients, where a clinical response was reported, 24 patients showed a complete response, 27 patients showed a partial response, 40 patients showed a minor response. The total response rate (RR) was 91/384 reported patients, 161 patients had a stable disease, 129 patients had progressive disease. A decrease in tumor volume was only described in three patients. Side effects of CIK cell treatment were minor. Interestingly, a reduction of hepatitis B virus load was described in patients undergoing treatment with CIK cells. Disease-free survival rates were significantly higher in patients treated with CIK cells than in a control group without CIK treatment.
Adjuvant immunotherapy with cytokine-induced killer cells may prevent recurrence and improve quality of life and progression-free survival rates in patients with cancer.
最近，一种被称为“细胞因子诱导的杀伤（CIK）细胞”的自然杀伤 T 淋巴细胞亚群被描述。为了建立一个国际登记处，我们从文献和各自的研究人员那里收集了使用 CIK 细胞治疗癌症患者的临床数据和治疗方法。该登记处有望为使用 CIK 细胞的临床试验结果报告设定一套新标准。标准化报告系统将加速发现，并使我们能够改进治疗方法，使患者受益。
我们在 PubMed 中搜索了“CIK 细胞临床试验”。
在 867 个匹配项中，确定了 11 项使用 CIK 细胞的临床试验。在这些试验中，共治疗了 426 名患者，其中 313 名男性，113 名女性。大多数试验包括男性肝癌、胃癌、霍奇金或非霍奇金病患者。在 11 项研究中有 10 项使用了自体 CIK 细胞。注射的 CIK 细胞总数范围从 2.1×10^7 到 5.2×10^10。每次输注的 CIK 细胞数范围从 7.2×10^6 到 2.1×10^10。患者接受多达 40 次 CIK 细胞输注。在报告了临床反应的 384 名患者中，24 名患者出现完全缓解，27 名患者出现部分缓解，40 名患者出现轻微缓解。总有效率（RR）为 384 例报告患者中的 91/384 例，161 例患者疾病稳定，129 例患者疾病进展。只有 3 名患者的肿瘤体积减小。CIK 细胞治疗的副作用较小。有趣的是，在接受 CIK 细胞治疗的患者中，乙型肝炎病毒载量降低。与未接受 CIK 治疗的对照组相比，接受 CIK 细胞治疗的患者无病生存率显著提高。
细胞因子诱导的杀伤细胞辅助免疫治疗可能预防癌症患者复发，提高生活质量和无进展生存率。
